Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

BillionToOne

Request full access

The only genetic testing platform that accurately and efficiently detects and measures disease at the molecular level

Menlo Park, United StatesFounded 2016Biotech & Life Sciences

About BillionToOne

BillionToOne is a biotechnology startup that operates in the healthcare sector, specifically in the field of molecular diagnostics. The company's proprietary technology, known as QCT, has the ability to detect and quantify disease at a single base-pair resolution. This means it can identify the tiniest variations in our DNA, which consists of three billion letters or nucleotides.

The company's primary focus is on prenatal screening and oncology testing. Their products, Northstar Select™ and Northstar Response™, are commercially available. Northstar Select™ is used to determine the most suitable first line therapy for patients, while Northstar Response™ monitors the effectiveness of the therapy.

BillionToOne's business model revolves around providing these diagnostic services to healthcare providers. They generate revenue by selling their testing services to these providers, who then use the results to guide their treatment plans.

The company's mission is to make molecular testing more accurate, efficient, and accessible to all. They are driven by a culture of growth, equality, and teamwork, with a strong focus on making a positive impact in healthcare.

The company was founded by Oguzhan Atay, Ph.D., and David Tsao, Ph.D., and is comprised of a team of engineers, scientists, and industry experts who are passionate about improving healthcare through their innovative technology.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2025

BillionToOne in the Menlo Park ecosystem

Live from Dealroom

The BillionToOne office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

21 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed6 investors entered at this stage

Series A9 investors entered at this stage

Series B and later6 investors entered at this stage

Employees mapped 834 incl. 7 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 8 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$26M

17 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See BillionToOne on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.